The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAegon Ord Regulatory News (0Q0Y)

Share Price Information for Aegon Ord (0Q0Y)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.894
Bid: 5.60
Ask: 6.188
Change: -0.023 (-0.39%)
Spread: 0.588 (10.50%)
Open: 5.886
High: 5.894
Low: 5.882
Prev. Close: 5.917
0Q0Y Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Nominations EB and SB AEGON N.V.

31 Mar 2011 07:00

Nominations Executive Board and Supervisory Board AEGON N.V.

Shareholders of AEGON N.V. will be asked at the upcoming Annual General meetingof Shareholders (AGM) onMay 12, 2011 to reappoint Mr. Alex Wynaendts as member of the Executive Board for a four-year term.

Shareholders will also be asked to reappoint Mr. Antony Burgmans, Ms. Karla Peijs and Mr. Leo van Wijk as members of the Supervisory Board for a four-year term.

More information about the proposed reappointments is contained in the agendaof the AGM on May 12, 2011, which is available on AEGON's corporate website,www.aegon.com. Contact informationMedia relations: Greg Tucker+31(0)70 344 8956gcc-ir@aegon.com

Investor relations: Gerbrand Nijman

+31 (0)70 344 8305

877 548 9668 - toll free USA only

ir@aegon.comwww.aegon.comAbout AEGON

As an international life insurance, pension and asset management company based in The Hague, AEGON has businesses in over twenty markets in the Americas, Europe and Asia. AEGON companies employ approximately 27,500 people and have some 40 million customers across the globe.

Key figures - EUR Full year 2010 Full year 2009 Underlying earnings 2.0 billion 1.2 billion before tax New life sales 2.2 billion 2.1 billion Gross deposits (excl. 33 billion 28 billion run-off) Revenue generating 413 billion 363 billion investments (end of period) Forward-looking statementsThe statements contained in this document that are not historical facts areforward-looking statements as defined in the US Private Securities LitigationReform Act of 1995. The following are words that identify such forward-lookingstatements: aim, believe, estimate, target, intend, may, expect, anticipate,predict, project, counting on, plan, continue, want, forecast, goal, should,would, is confident, will, and similar expressions as they relate to AEGON.These statements are not guarantees of future performance and involve risks,uncertainties and assumptions that are difficult to predict. We undertake noobligation to publicly update or revise any forward-looking statements. Readersare cautioned not to place undue reliance on these forward-looking statements,which merely reflect company expectations at the time of writing. Actualresults may differ materially from expectations conveyed in forward-lookingstatements due to changes caused by various risks and uncertainties. Such risksand uncertainties include but are not limited to the following:

* Changes in general economic conditions, particularly in the United States,

the Netherlands and the United Kingdom; * Changes in the performance of financial markets, including emerging markets, such as with regard to: *

+ The frequency and severity of defaults by issuers in our fixed income

investment portfolios; and

+ The effects of corporate bankruptcies and/or accounting restatements on

the financial markets and the resulting decline in the value of equity

and debt securities we hold; * The frequency and severity of insured loss events;

* Changes affecting mortality, morbidity, persistence and other factors that

may impact the profitability of our insurance products; * Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels;

* Changes affecting currency exchange rates, in particular the EUR/USD and

EUR/GBP exchange rates; * Increasing levels of competition in the Americas, the Netherlands, the United Kingdom and new markets; * Changes in laws and regulations, particularly those affecting our operations, the products we sell, and the attractiveness of certain products to our consumers;

* Regulatory changes relating to the insurance industry in the jurisdictions

in which we operate; * Acts of God, acts of terrorism, acts of war and pandemics; * Changes in the policies of central banks and/or governments; * Lowering of one or more of our debt ratings issued by recognized rating

organizations and the adverse impact such action may have on our ability to

raise capital and on our liquidity and financial condition;

* Lowering of one or more of insurer financial strength ratings of our

insurance subsidiaries and the adverse impact such action may have on the

premium writings, policy retention, profitability of its insurance subsidiaries and liquidity; * The effect of the European Union's Solvency II requirements and other

regulations in other jurisdictions affecting the capital we are required to

maintain;

* Litigation or regulatory action that could require us to pay significant

damages or change the way we do business; * Customer responsiveness to both new products and distribution channels;

* Competitive, legal, regulatory, or tax changes that affect the distribution

cost of or demand for our products; * The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including our ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions; * Our failure to achieve anticipated levels of earnings or operational efficiencies as well as other cost saving initiatives;

* Our inability to obtain consent from the Dutch Central Bank to repurchase

our Core Capital Securities; and

* Our inability to divest Transamerica Reinsurance on terms acceptable to us.

Further details of potential risks and uncertainties affecting the company aredescribed in the company's filings with Euronext Amsterdam and the USSecurities and Exchange Commission, including the Annual Report on Form 20-F.These forward-looking statements speak only as of the date of this document.Except as required by any applicable law or regulation, the company expresslydisclaims any obligation or undertaking to release publicly any updates orrevisions to any forward-looking statements contained herein to reflect anychange in the company's expectations with regard thereto or any change inevents, conditions or circumstances on which any such statement is based.

vendor
12
Date   Source Headline
29th Jun 20127:00 amPRNAEGON's listing on the London Stock Exchange cancelled
19th Jun 20127:00 amPRNAEGON defines path for capturing growth in core markets
8th Jun 20126:30 pmPRNStock fraction final dividend 2011 AEGON at 1/33
31st May 20127:00 amPRNAEGON accelerates improvements NL unit-linked policies
23rd May 20127:00 amPRNAEGON to cancel its listing on the LSE
16th May 20124:00 pmPRNSummary of Annual General Meeting of Shareholders
10th May 20127:00 amPRNQ1 2012 Results
10th May 20127:00 amPRNAEGON's 2011 total EV increased 10% to EUR 20.7 billion
12th Apr 20127:00 amPRNAEGON recategorizes reporting Asian operations
4th Apr 20127:00 amPRNAEGON N.V. publishes agenda AGM
23rd Mar 20123:15 pmPRNAEGON files Annual Report 2011
17th Feb 20127:00 amPRNAEGON UK CEO Adrian Grace appointed to Management Board
17th Feb 20127:00 amPRNAEGON maintains strong capital position
27th Jan 20127:00 amPRNAEGON into EUR 2 billion syndicated credit facility
25th Jan 20127:15 amPRNUSD 500 mln 8% non-cumulative subordinated notes
6th Dec 20117:00 amPRNAEGON to reaffirm targets at annual investor conference
24th Nov 20117:00 amPRNAEGON completes sale of Guardian in the UK
10th Nov 20117:00 amPRN3rd Quarter Results
29th Sep 20117:30 amPRNAEGON to Restructure Business in the Netherlands
16th Aug 20117:00 amPRNAEGON to Sell Closed UK Life Insurance Business Guardian
11th Aug 20117:00 amPRNQ2 2011 Results
10th Aug 20117:00 amPRNAEGON completes divestment of Transamerica Reinsurance
8th Aug 20117:00 amPRNMr Docters van Leeuwen steps down from Supervisory Board
15th Jun 20117:00 amPRNAEGON completes repayment to Dutch State
12th May 20115:25 pmPRNSummary of Annual General Meeting of Shareholders
12th May 20117:00 amPRNAEGON's 2010 Total Embedded Value Increased to EUR18.9bn
12th May 20117:00 amPRNAEGON announces Q1 net income of EUR 327 million
26th Apr 20117:00 amPRNAEGON to divest Transamerica Reinsurance to SCOR
14th Apr 20117:00 amPRNCompletes Sale of EUR1.5 bn `SAECURE 10' RMBS notes
31st Mar 20113:00 pmPRNAEGON’s 2010 Form 20-F and Annual Report available
31st Mar 20117:00 amPRNNominations EB and SB AEGON N.V.
16th Mar 20117:00 amPRNAEGON repurchased EUR750 mln core capital securities
8th Mar 20117:00 amPRNAEGON appoints Adrian Grace CEO AEGON UK
24th Feb 20113:50 pmPRNAEGON completes 10% equity issue
24th Feb 20117:00 amPRNAEGON to launch equity issue of 10%
24th Feb 20117:00 amPRNAEGON announces strong Q4 2010 results
16th Feb 20117:00 amPRNAEGON Supervisory Board Member Cecelia Kempler to Resign
16th Dec 201011:42 amPRNAEGON UK response to FSA notice re Scottish Equitable
8th Dec 20107:00 amPRNAEGON to detail progress in execution of strategy
2nd Dec 20107:00 amPRNAEGON to sharpen focus on core activities in US
27th Sep 20104:45 pmPRNAEGON completes sale of EUR 842 million RMBS notes
7th Sep 20107:00 amPRNAEGON appoints Global Head of Sustainability
31st Aug 20107:00 amPRNAEGON repays EUR 500 million of government support
17th Aug 20107:00 amPRNAEGON concludes approval process European Commission
12th Aug 20107:00 amPRNAEGON posts strong results for second quarter 2010
13th Jul 20107:00 amPRNMs Russell appointed CEO AEGON Asset Management business
8th Jul 20107:00 amPRNAEGON completes sale of EUR 1 billion RMBS notes
6th Jul 20107:00 amPRNAEGON appoints global head of human resources
22nd Jun 20107:00 amPRNStatement re Strategy
1st Jun 20107:00 amPRNAEGON appoints Clare Bousfield CFO in UK
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.